Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by HepaRegeniX

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: $12.2 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 21, 2020

            Details:

            The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.